The ARG1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the human ARG1 gene encoding arginase 1 has been disrupted. This loss-of-function model provides a robust platform for investigating arginine metabolism and its downstream effects without reliance on pharmacological inhibitors. By eliminating endogenous arginase activity, the cells enable precise dissection of arginine-dependent signaling pathways and metabolic networks.
The host cell line, HEK293T, is a human embryonic kidney epithelial cell line constitutively expressing the SV40 large T antigen, which facilitates episomal replication of plasmids and yields high transfection efficiency. This background makes HEK293T cells a preferred system for transient protein expression, lentiviral production, and metabolic engineering studies. Their robust growth and ease of manipulation allow reproducible experiments in the context of a human cellular environment, even for genes not typically expressed in kidney tissue.
The ARG1 gene product, arginase 1, catalyzes the hydrolysis of L-arginine to L-ornithine and urea, a key step in the urea cycle. ARG1 is transcriptionally activated by IL-4 and IL-13 through STAT6, and is also regulated by TGF-??, GM-CSF, and HIF-1??. Functionally, it depletes arginine from the microenvironment, suppressing nitric oxide synthesis by competing with NOS2, while supplying ornithine for polyamine biosynthesis via ODC1 and for proline production via PRODH. Interacting with manganese ions and urea cycle enzymes ASS1 and ASL, ARG1 integrates nitrogen disposal with cell growth and immune modulation. Knockout of ARG1 disrupts the urea cycle, alters polyamine and proline pools, and relieves arginine-dependent immunosuppression.
In the HEK293T background, ARG1 knockout generates a controlled system for studying arginine metabolic flux without interference from native arginase. Given HEK293T cells’ widespread use in cancer biology, this model allows researchers to reconstitute ARG1-null conditions to explore tumor immune evasion mechanisms or to evaluate the impact of exogenous arginase on T-cell anergy. It also provides a clean host for engineering ornithine-derived compound production, as the knockout removes a major competing pathway, channeling arginine toward alternative fates.
These polyclonal knockout cells are suitable for a range of applications, including investigation of urea cycle disorders such as hyperargininemia, analysis of arginine metabolism in hepatocellular carcinoma and other cancers, and restoration of T-cell function via arginine supplementation. They facilitate screening of ARG1 inhibitors, studying mTOR pathway activation in response to arginine availability, and metabolic engineering for polyamine or proline overproduction. Typical assays include urea production measurements, arginine consumption tracking, ornithine ELISA, HPLC-based amino acid profiling, T-cell proliferation assays, RT-qPCR for ARG1 expression, and flow cytometry for immune markers. Metabolomics and cell viability assessments under arginine deprivation further support mechanism-of-action studies. For further information or to discuss custom projects, please contact Ascent Research.
